Treatment of acrodermatitis continua of Hallopeau with adalimumab

Authors


  • Conflicts of interest: S.R. has acted as a consultant and advisor for Wyeth, Schering Plough and Abbott Pharmaceuticals; B.K. has acted as a consultant and advisor for Wyeth, Merck-Serono Ltd and Abbott Pharmaceuticals.

No abstract is available for this article.

Ancillary